Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
GHDX's Cash-to-Debt is ranked higher than
99% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. GHDX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GHDX' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.9  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.80
GHDX's Equity-to-Asset is ranked higher than
77% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. GHDX: 0.80 )
Ranked among companies with meaningful Equity-to-Asset only.
GHDX' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.56  Med: 0.79 Max: 0.89
Current: 0.8
-3.56
0.89
Interest Coverage No Debt
GHDX's Interest Coverage is ranked higher than
99% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. GHDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GHDX' s Interest Coverage Range Over the Past 10 Years
Min: 80.08  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 7
Altman Z-Score: 15.44
Beneish M-Score: -1.69
WACC vs ROIC
6.31%
1.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -2.86
GHDX's Operating Margin % is ranked lower than
56% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. GHDX: -2.86 )
Ranked among companies with meaningful Operating Margin % only.
GHDX' s Operating Margin % Range Over the Past 10 Years
Min: -46.33  Med: -5.5 Max: 4.01
Current: -2.86
-46.33
4.01
Net Margin % -2.53
GHDX's Net Margin % is ranked lower than
54% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. GHDX: -2.53 )
Ranked among companies with meaningful Net Margin % only.
GHDX' s Net Margin % Range Over the Past 10 Years
Min: -42.63  Med: -5.59 Max: 3.81
Current: -2.53
-42.63
3.81
ROE % -5.68
GHDX's ROE % is ranked lower than
55% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. GHDX: -5.68 )
Ranked among companies with meaningful ROE % only.
GHDX' s ROE % Range Over the Past 10 Years
Min: -48.31  Med: -11.7 Max: 7.79
Current: -5.68
-48.31
7.79
ROA % -4.39
GHDX's ROA % is ranked lower than
53% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. GHDX: -4.39 )
Ranked among companies with meaningful ROA % only.
GHDX' s ROA % Range Over the Past 10 Years
Min: -37.4  Med: -9.24 Max: 6.18
Current: -4.39
-37.4
6.18
ROC (Joel Greenblatt) % -18.72
GHDX's ROC (Joel Greenblatt) % is ranked lower than
56% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. GHDX: -18.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GHDX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -299.12  Med: -55.36 Max: 74.51
Current: -18.72
-299.12
74.51
3-Year Revenue Growth Rate 4.80
GHDX's 3-Year Revenue Growth Rate is ranked higher than
50% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. GHDX: 4.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GHDX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 12.6 Max: 136.5
Current: 4.8
0
136.5
3-Year EBITDA Growth Rate 2.50
GHDX's 3-Year EBITDA Growth Rate is ranked higher than
50% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. GHDX: 2.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GHDX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -59.8  Med: -54.7 Max: 2.5
Current: 2.5
-59.8
2.5
GuruFocus has detected 1 Warning Sign with Genomic Health Inc $GHDX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GHDX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

GHDX Guru Trades in Q2 2016

Paul Tudor Jones 11,800 sh (New)
Chuck Royce 88,500 sh (+15.69%)
Jim Simons 436,100 sh (-2.22%)
» More
Q3 2016

GHDX Guru Trades in Q3 2016

Columbia Wanger 468,556 sh (New)
Jim Simons 547,600 sh (+25.57%)
Chuck Royce 68,500 sh (-22.60%)
Paul Tudor Jones 7,600 sh (-35.59%)
» More
Q4 2016

GHDX Guru Trades in Q4 2016

Columbia Wanger 1,275,338 sh (+172.18%)
Jim Simons 576,700 sh (+5.31%)
Paul Tudor Jones Sold Out
Chuck Royce 1,200 sh (-98.25%)
» More
Q1 2017

GHDX Guru Trades in Q1 2017

Jim Simons 733,200 sh (+27.14%)
Columbia Wanger 1,607,649 sh (+26.06%)
Chuck Royce 1,200 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with GHDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NAS:KANG, NAS:ABAX, NAS:MEDP, NAS:ALOG, NAS:BEAT, NAS:QDEL, NAS:VREX, NAS:FMI, NAS:HSKA, NAS:NRCIA, NAS:LNTH, NAS:MYGN, NAS:NEO, NAS:VIVO, NYSE:ARA, NAS:NTRA, NAS:AXDX, NYSE:ENZ, NAS:NVDQ, NYSE:NVTA » details
Traded in other countries:G7H.Germany,
Headquarter Location:USA
Genomic Health Inc is a healthcare company. It provides genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer.

Genomic Health Inc was incorporated in Delaware in August 2000. It is a healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The Company is engaged in the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The Company's Oncotype DX breast and colon tests have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company provides its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ, or DCIS and a Genomic Prostate Score, or GPS, for prostate cancer. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, or RT-PCR, in standard tumor pathology specimens to provide tumor-specific information, or the "oncotype" of a tumor. It has a direct commercial presence with employees and consultants in the United States and certain other countries, and its Oncotype DX breast and colon cancer tests are also available outside of the United States through a network of distributors. The Company faces competition from companies that offer products or have conducted research to profile genes, gene expression or protein expression in breast, colon or prostate cancer, including public companies such as, GE Healthcare, a business unit of General Electric Company, Hologic, Inc., Myriad Genetics, Inc., NanoString Technologies, Inc., Novartis AG, Qiagen N.V. and Response Genetics, Inc., and many private companies. It faces competition from commercial laboratories with distribution networks for diagnostic tests, such as Laboratory Corporation of America Holdings and Quest Diagnostics Incorporated. The Company holds 40 issued patents in the United States and 94 issued patents outside of the United States. As a clinical reference laboratory, the Company is subject to hold certain federal, state and local licenses, certifications and permits to conduct its business.

Ratios

vs
industry
vs
history
PB Ratio 6.47
GHDX's PB Ratio is ranked lower than
75% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. GHDX: 6.47 )
Ranked among companies with meaningful PB Ratio only.
GHDX' s PB Ratio Range Over the Past 10 Years
Min: 4.44  Med: 7.07 Max: 14.28
Current: 6.47
4.44
14.28
PS Ratio 3.10
GHDX's PS Ratio is ranked higher than
52% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. GHDX: 3.10 )
Ranked among companies with meaningful PS Ratio only.
GHDX' s PS Ratio Range Over the Past 10 Years
Min: 2.17  Med: 3.88 Max: 20.45
Current: 3.1
2.17
20.45
Price-to-Free-Cash-Flow 7652.50
GHDX's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. GHDX: 7652.50 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GHDX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 34.46  Med: 59.9 Max: 14545
Current: 7652.5
34.46
14545
Price-to-Operating-Cash-Flow 52.24
GHDX's Price-to-Operating-Cash-Flow is ranked lower than
94% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. GHDX: 52.24 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GHDX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 27.44  Med: 51.78 Max: 1560.53
Current: 52.24
27.44
1560.53
EV-to-EBIT -101.22
GHDX's EV-to-EBIT is ranked lower than
99.99% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. GHDX: -101.22 )
Ranked among companies with meaningful EV-to-EBIT only.
GHDX' s EV-to-EBIT Range Over the Past 10 Years
Min: -791  Med: -20.3 Max: 514.8
Current: -101.22
-791
514.8
EV-to-EBITDA -3310.65
GHDX's EV-to-EBITDA is ranked lower than
99.99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. GHDX: -3310.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
GHDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3540.2  Med: -20.1 Max: 939.6
Current: -3310.65
-3540.2
939.6
Current Ratio 3.86
GHDX's Current Ratio is ranked higher than
64% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. GHDX: 3.86 )
Ranked among companies with meaningful Current Ratio only.
GHDX' s Current Ratio Range Over the Past 10 Years
Min: 3.26  Med: 4.52 Max: 15.83
Current: 3.86
3.26
15.83
Quick Ratio 3.86
GHDX's Quick Ratio is ranked higher than
69% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. GHDX: 3.86 )
Ranked among companies with meaningful Quick Ratio only.
GHDX' s Quick Ratio Range Over the Past 10 Years
Min: 3.26  Med: 4.52 Max: 15.83
Current: 3.86
3.26
15.83
Days Sales Outstanding 38.15
GHDX's Days Sales Outstanding is ranked higher than
80% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. GHDX: 38.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
GHDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.15  Med: 35.94 Max: 47.19
Current: 38.15
27.15
47.19
Days Payable 34.68
GHDX's Days Payable is ranked lower than
84% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. GHDX: 34.68 )
Ranked among companies with meaningful Days Payable only.
GHDX' s Days Payable Range Over the Past 10 Years
Min: 14.62  Med: 43.28 Max: 75.79
Current: 34.68
14.62
75.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.00
GHDX's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. GHDX: -3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GHDX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -197.9  Med: -3.1 Max: -1
Current: -3
-197.9
-1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 19.37
GHDX's Price-to-Net-Cash is ranked lower than
68% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.15 vs. GHDX: 19.37 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GHDX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 12.34 Max: 23.16
Current: 19.37
0
23.16
Price-to-Net-Current-Asset-Value 10.27
GHDX's Price-to-Net-Current-Asset-Value is ranked lower than
58% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. GHDX: 10.27 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GHDX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 8.52 Max: 17
Current: 10.27
0
17
Price-to-Tangible-Book 6.46
GHDX's Price-to-Tangible-Book is ranked lower than
59% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. GHDX: 6.46 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GHDX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.3  Med: 6.99 Max: 11.76
Current: 6.46
3.3
11.76
Price-to-Intrinsic-Value-Projected-FCF 11.68
GHDX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
89% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. GHDX: 11.68 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GHDX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 5.71 Max: 37.9
Current: 11.68
0
37.9
Price-to-Median-PS-Value 0.80
GHDX's Price-to-Median-PS-Value is ranked higher than
71% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. GHDX: 0.80 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GHDX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.99 Max: 4.08
Current: 0.8
0
4.08
Earnings Yield (Greenblatt) % -0.95
GHDX's Earnings Yield (Greenblatt) % is ranked lower than
63% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. GHDX: -0.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GHDX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1.04  Med: 0.9 Max: 1.3
Current: -0.95
-1.04
1.3

More Statistics

Revenue (TTM) (Mil) $331.0
EPS (TTM) $ -0.24
Beta0.68
Short Percentage of Float3.82%
52-Week Range $24.81 - 33.96
Shares Outstanding (Mil)34.34

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 356 394 443
EPS ($) -0.03 0.32 0.64
EPS without NRI ($) -0.03 0.32 0.64
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for GHDX

Headlines

Articles On GuruFocus.com
Genomic Health to Present at Jefferies 2017 Healthcare Conference May 25 2017 
Prospective Oncotype DX® Genomic Prostate Score™ Test Data Presented at AUA and Published in Urol May 13 2017 
Oncotype DX® Genomic Prostate Score™ (GPS) Test Predicts 10-year Risk of Prostate Cancer-specific May 12 2017 
Genomic Health to Present at Bank of America Merrill Lynch 2017 Health Care Conference May 10 2017 
Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress May 09 2017 
Genomic Health Announces Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for May 04 2017 
Genomic Health Announces Upcoming Presentation of Four Oncotype DX® Studies Including New Validatio May 04 2017 
Genomic Health to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 02 2017 
Oncotype DX® Predicts 10-year Risk of Developing Metastatic Prostate Cancer in Low- and Intermedi Mar 31 2017 
Insiders Sell Alphabet, Facebook Aug 19 2016 

More From Other Websites
Genomic Health to Present at Jefferies 2017 Healthcare Conference May 25 2017
Genomic Health Q1 Results Weak, Cancer Test Business Strong May 17 2017
Genomic Health's (GHDX) Oncotype DX GPS Test Data Positive May 16 2017
Genomic Health, Inc. Waits for Reimbursement May 15 2017
Edited Transcript of GHDX earnings conference call or presentation 9-May-17 8:30pm GMT May 14 2017
Prospective Oncotype DX® Genomic Prostate Score™ Test Data Presented at AUA and Published in... May 13 2017
Genomic Health, Inc. – Value Analysis (NASDAQ:GHDX) : May 12, 2017 May 12 2017
Oncotype DX® Genomic Prostate Score™ (GPS) Test Predicts 10-year Risk of Prostate Cancer-specific... May 12 2017
Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates May 11 2017
Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : May 11, 2017 May 11 2017
Genomic Health to Present at Bank of America Merrill Lynch 2017 Health Care Conference May 10 2017
Genomic Health reports 1Q loss May 09 2017
Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress May 09 2017
Investor Network: Genomic Health, Inc. to Host Earnings Call May 09 2017
Blog Coverage: Genomic Health Announces Favorable LCD on Medicare Coverage for Use of Oncotype DX... May 08 2017
Genomic Health Announces Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for... May 04 2017
Genomic Health Announces Upcoming Presentation of Four Oncotype DX® Studies Including New... May 04 2017
Genomic Health to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday,... May 02 2017
Zacks.com featured highlights: Cabot Oil & Gas, Cardiovascular Systems, Fortress Transportation and... Apr 26 2017
Genomic Health's GPS Predicts Metastatic Prostate Cancer Mar 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)